国际经济与贸易学院知识库

随着经济全球化程度的不断加深，医药企业在政策扶持下不断加大研发投入并积极开展国际化经营，推动了中国“走出去”战略的顺利实施。但医药企业仍存在着创新不足的问题，研发创新强度与发达国家存在着一定差距。中国“十四五”规划提出，要加强企业创新的主导地位，促进各种创新要素向企业集聚，鼓励企业加大研发投入。因此，在新经济环境下，探究研发投入对医药企业国际化绩效的影响，对中国医药企业国际化发展具有重要的意义。再加之复星医药作为以创新研发为主导的医药企业，研发投入与国际化发展情况均位居前列，在中国医药行业中处于遥遥领先地位。所以本文选取了中国医药行业代表性企业复星医药作为研究对象，探究其研发投入对其国际化绩效的影响。

本文介绍了复星医药的国际化发展动因、战略进程以及研发投入现状，分析了研发投入对国际化绩效影响的作用机理。在此基础上，使用定量分析的方法，利用复星医药集团2010-2020年的企业数据，研究复星医药研发投入与其国际化绩效的关系，同时做出相关变化趋势图研究其影响的具体变化。研究结果表明：第一，复星医药研发投入对其国际化绩效呈正向作用，随研发投入的增加国际化绩效也增加。第二，复星医药研发投入强度对国际化绩效的影响幅度存在差异，每亿元研发投入引起国际化绩效的增幅不同。据此本文建议：复星医药要充分依托国家政策，健全全程管理制度，合理安排研发投入力度，积极防范国内外风险，努力打造特色专属医药产品，进而促进复星医药国际化绩效的提升。

With the deepening of economic globalization, pharmaceutical enterprises continue to increase R&D investment and actively carry out international operation with policy support, which has promoted the smooth implementation of China's "going global" strategy. However, pharmaceutical enterprises still have the problem of insufficient innovation, and there is a certain gap between R&D innovation intensity and developed countries. China's 14th five year plan proposes to strengthen the leading position of enterprise innovation, promote the agglomeration of various innovation elements to enterprises, and encourage enterprises to increase R&D investment. Therefore, in the new economic environment, exploring the impact of R&D investment on the international performance of pharmaceutical enterprises is of great significance to the international development of Chinese pharmaceutical enterprises. In addition, as a pharmaceutical enterprise dominated by innovative R&D, Fosun Pharmaceutical ranks in the forefront of R&D investment and international development, and is far ahead in China's pharmaceutical industry. Therefore, this dissertation selects Fosun Pharmaceutical, a representative enterprise in China's pharmaceutical industry, as the research object to explore the impact of its R&D investment on its international performance.

This dissertation introduces the international development motivation, strategic process and the current situation of R&D investment of Fosun Pharmaceutical Group, and analyzes the mechanism of the impact of R & D investment on international performance. On this basis, using the method of quantitative analysis and the enterprise data of Fosun Pharmaceutical Group from 2010 to 2020, this dissertation studies the relationship between Fosun Pharmaceutical R&D investment and its international performance, and makes relevant change trend charts to study the specific changes of its impact. The results show that: first, Fosun Pharmaceutical R&D investment has a positive effect on its internationalization performance, and the internationalization performance also increases with the increase of R&D investment. Second, there are differences in the impact of Fosun Pharmaceutical R&D investment intensity on international performance. Every 100 million yuan of R&D investment leads to different growth of international performance. Therefore, this dissertation suggests that Fosun Pharmaceutical should fully rely on national policies, improve the whole process management system, reasonably arrange R&D investment, actively prevent domestic and foreign risks, and strive to create characteristic exclusive pharmaceutical products, so as to promote the internationalization performance of Fosun Pharmaceutical.